Adaptive Biotechnologies Corporation (FRA:1HM)
Germany
· Delayed Price · Currency is EUR 13.40
-1.16 (-8.00%)
At close: Dec 5, 2025
Adaptive Biotechnologies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | 252.75 | 178.96 | 170.28 | 185.31 | 154.34 | 98.38 | Upgrade
|
| Revenue Growth (YoY) | 42.57% | 5.10% | -8.11% | 20.06% | 56.88% | 15.65% | Upgrade
|
| Cost of Revenue | 88.26 | 89.16 | 96.02 | 75.6 | 191.64 | 138.6 | Upgrade
|
| Gross Profit | 164.49 | 89.8 | 74.26 | 109.71 | -37.3 | -40.22 | Upgrade
|
| Selling, General & Admin | 162.87 | 157.57 | 172.51 | 184.13 | 169.97 | 110.89 | Upgrade
|
| Research & Development | 78.12 | 85.87 | 101.65 | 124.07 | - | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | Upgrade
|
| Operating Expenses | 242.68 | 245.14 | 275.86 | 309.9 | 171.67 | 112.6 | Upgrade
|
| Operating Income | -78.19 | -155.34 | -201.61 | -200.19 | -208.97 | -152.82 | Upgrade
|
| Interest Expense | -11.78 | -11.58 | -13.8 | -4.24 | - | - | Upgrade
|
| Interest & Investment Income | 6.69 | 6.33 | 6.35 | 4.8 | 8.9 | 7.36 | Upgrade
|
| EBT Excluding Unusual Items | -83.28 | -160.6 | -209.06 | -199.63 | -200.07 | -145.45 | Upgrade
|
| Merger & Restructuring Charges | -7.21 | -7.21 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.68 | 8.21 | 9.18 | -0.74 | -7.23 | -0.77 | Upgrade
|
| Asset Writedown | 7.21 | - | -25.43 | - | - | - | Upgrade
|
| Pretax Income | -79.6 | -159.6 | -225.3 | -200.37 | -207.3 | -146.23 | Upgrade
|
| Earnings From Continuing Operations | -79.6 | -159.6 | -225.3 | -200.37 | -207.3 | -146.23 | Upgrade
|
| Minority Interest in Earnings | -0.02 | 0.1 | 0.05 | 0.18 | 0.02 | - | Upgrade
|
| Net Income | -79.61 | -159.49 | -225.25 | -200.19 | -207.28 | -146.23 | Upgrade
|
| Net Income to Common | -79.61 | -159.49 | -225.25 | -200.19 | -207.28 | -146.23 | Upgrade
|
| Shares Outstanding (Basic) | 150 | 147 | 144 | 143 | 140 | 131 | Upgrade
|
| Shares Outstanding (Diluted) | 150 | 147 | 144 | 143 | 140 | 131 | Upgrade
|
| Shares Change (YoY) | 2.70% | 1.88% | 1.31% | 1.54% | 6.96% | 89.71% | Upgrade
|
| EPS (Basic) | -0.53 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | Upgrade
|
| EPS (Diluted) | -0.53 | -1.08 | -1.56 | -1.40 | -1.48 | -1.11 | Upgrade
|
| Free Cash Flow | -62.94 | -98.88 | -167.02 | -200.29 | -254.47 | -168.49 | Upgrade
|
| Free Cash Flow Per Share | -0.42 | -0.67 | -1.16 | -1.41 | -1.81 | -1.28 | Upgrade
|
| Gross Margin | 65.08% | 50.18% | 43.61% | 59.20% | -24.17% | -40.88% | Upgrade
|
| Operating Margin | -30.93% | -86.80% | -118.40% | -108.03% | -135.39% | -155.33% | Upgrade
|
| Profit Margin | -31.50% | -89.12% | -132.28% | -108.03% | -134.30% | -148.63% | Upgrade
|
| Free Cash Flow Margin | -24.90% | -55.25% | -98.09% | -108.09% | -164.87% | -171.26% | Upgrade
|
| EBITDA | -60.1 | -136.09 | -179.38 | -179.27 | -195.01 | -144.35 | Upgrade
|
| EBITDA Margin | -23.78% | -76.05% | -105.34% | -96.74% | -126.35% | -146.72% | Upgrade
|
| D&A For EBITDA | 18.09 | 19.26 | 22.23 | 20.92 | 13.95 | 8.47 | Upgrade
|
| EBIT | -78.19 | -155.34 | -201.61 | -200.19 | -208.97 | -152.82 | Upgrade
|
| EBIT Margin | -30.93% | -86.80% | -118.40% | -108.03% | -135.39% | -155.33% | Upgrade
|
| Advertising Expenses | - | 6.1 | 8.6 | 13.7 | - | 14.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.